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between the compliant/persistent and non-compliant/non-persis-
tent groups for other cardiovascular risk factors (age, diabetes,
smoking status, cholesterol, and alcohol). RESULTS: Compliant
patients (those with medication-possession ratios >80%) had 12-
month average systolic and diastolic BP values 3.5mmHg (p <
0.0005) and 0.5mmHg (non-signiﬁcant) lower, respectively, than
those of non-compliant patients. Assuming these differences
remain over time, the Glynn algorithms predict a 4.6% decrease
(95% conﬁdence interval 2.4%, 6.9%) in the relative risk of
adverse cardiovascular outcomes for men and a 16.3% decrease
(95% CI 12.2%, 20.6%) for women. Persistent patients (those
remaining on valsartan therapy for 12 months) had ﬁnal systolic
and diastolic BP values 4.1mmHg and 2.5mmHg (both p < 0.05)
lower than those for non-persistent patients, projecting an 8.4%
decrease (95% CI 3.1%, 13.9%) in relative risk of adverse car-
diovascular outcomes for men and a 26.6% decrease (95% CI
19.8%, 33.9%) for women. CONCLUSIONS: Compliance with
and persistence to hypertension therapy predicted substantial
decreases in adverse cardiovascular outcomes. These impacts
may also lead to improved patient-reported outcomes and
decreased costs, and can be used to assess long-term treatment
cost-effectiveness.
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OBJECTIVE: To determine the impact of adherence to antihy-
perlipidemic drug therapy on patients’ total pharmacy and
medical costs, from the payer’s perspective. METHODS: Retro-
spective database analysis of Maryland Medicaid medical and
pharmacy claims for the period January 1, 2001–December 31,
2003. Inclusion criteria: Continuously enrolled patients older
than 18 years who had at least one prescription claim for any of
the statins. Exclusion criteria (to obtain incident cohort): Patients
who had at least a claim before July 1st, 2002. Non-adherence
was deﬁned as a failure to reﬁll a prescription claim. General-
ized linear models with a logarithmic link function were used to
determine the impact of adherence to statins on medical costs,
after adjusting for age, gender, race and comorbidities by con-
structing a Charlson Comorbidity Index. RESULTS: Total of
2746 patients, 34% male, 44% African-Americans, and 65%
older than 63. Patients who adhere to their antihyperlipidemic
pharmacotherapy incur 26.08% (p < 0.0001; CI -0.41, -0.19)
and 33.25% (p = 0.0002; CI -0.62, -0.19) lower total costs
(pharmacy and medical) and medical costs respectively than
those who do not. Those between the age of 40 and 63 and those
who are African-American incur 19.22% (p < 0.0001; CI -0.31,
0.11) and 14.05% (p = 0.002; CI -0.25, -0.05) lower total costs
than those who are older than 63 and those who are Caucasian
respectively. A unit increase in the comorbidity index leads to a
10.13% (p < 0.0001; CI 0.07, 0.12) increase in total costs. CON-
CLUSIONS: On average, adherence to antihyperlipidemic phar-
macotherapy results in lower total costs. More awareness given
to adherence patterns on statins could lower the payers’ total
medical costs.
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OBJECTIVE: To identify the determinants of drug adherence
among statin users in a Medicaid managed care population.
METHODS: Retrospective database analysis of Maryland 
Medicaid medical and pharmacy claims for the period January
1, 2001–December 31, 2003. Inclusion criteria: Continuously
enrolled patients older than 18 years who had at least one pre-
scription claim for any of the statins. Exclusion criteria (to obtain
incident cohort): Patients who had at least a claim before July
1st, 2002. Non-adherence was deﬁned as a failure to reﬁll a pre-
scription claim. Logistic regression models were built to deter-
mine the association of age, gender, race, and comorbidities
(based on Charlson Comorbidity Index) with drug adherence.
RESULTS: Out of 1997 patients, 61% females, 57% African
Americans, and 70% 60 years old or younger. Caucasians were
more adherent than African Americans (30% vs. 22%), younger
patients less adherent than older patients (24% vs. 26%) and
females less adherent than males (22% vs. 28%). In the logistic
multivariate model, adjusting for demographics and comorbidi-
ties, African Americans (OR 0.68, 95% CI 0.549, 0.841), and
males (OR 1.33, 95% CI 1.083, 1.641) were signiﬁcantly more
likely to adhere to statin therapy. CONCLUSION: In this Med-
icaid population, adherence to statin pharmacotherapy is lower
among females and African Americans. The effectiveness of
adherence programs may be improved if they are earmarked to
these speciﬁc subpopulations.
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OBJECTIVE: To identify patient segments based on beliefs about
medications, reasons for non-adherence, and demographics to
inform actionable adherence improvement messaging.
METHODS: A total of 5630 patients self-identifying as having
high cholesterol responded to the Thomson Medstat PULSE con-
sumer health behavior survey in October–November 2005.
These respondents received cholesterol-speciﬁc questions about
their adherence, beliefs and reasons for non-adherence. Beliefs
about the necessity of and concerns about taking cholesterol-
lowering medications were assessed via ﬁve likert-scale ques-
tions, each with summed scores ranging between 5 and 25. A
cut-point of 15 was used to identify high versus low necessity 
or concern creating four patient segments: high necessity/
high concern (HNHC), low necessity/high concern (LNHC), low
necessity/low concern (LNLC), high necessity/low concern
(HNLC). Non-adherence was measured as skipping, taking
smaller doses, delaying, and/or stopping medication ﬁlls in the
past 30 days. Reasons for non-adherence included: cost, forget-
ting, experience with the medication, self-assessed need, and 
convenience. RESULTS: A total of 4737 respondents reported
taking prescription cholesterol-lowering medications with
28.1% reporting non-adherence. Non-adherence rates varied sig-
niﬁcantly among patient segments: 51.6% of LNHC respon-
dents, 36.1% of HNHC, 29.1% of LNLC and 20.8% of HNLC
were non-adherent (chi-square p < 0.0001). Type of and reasons
for non-adherence also varied. Patients with high concerns were
more likely to report taking smaller doses (33.5% of HNHC and
36.5% of LNHC versus 22.4% of LNLC and 20.6% of HNLC)
than those with low concerns and they were more likely to be
non-adherent due to experiences with medications (26.6% of
HNHC and 30.2% of LNHC versus 12.2% LNLC and 8.7% of
HNLC). Patient segments also differed by income (chi-square p
< 0.0001), education (chi-square p < 0.0001), and health status
(chi-square p < 0.0001). CONCLUSION: Creating psycho-
graphic patient segments using patient beliefs about medication
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necessity and concerns may be useful for crafting actionable mes-
saging to overcome barriers to medication adherence.
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OBJECTIVES: Determine the association between antihyperten-
sive medication class and blood pressure (BP) control and deter-
mine persistence of subjects on monotherapy for hypertension in
veterans. METHODS: Blood pressure (BP) measurements and
pharmacy records were obtained from Southern Arizona Veter-
ans Affairs Healthcare System. Variables of interest included
demographics, BP measurements, and pharmacy dispensings.
Medications classiﬁed by VA class codes included ten distinct
subclasses. Mean systolic BP (SBP) and diastolic BPs (DBP) were
categorized according to JNC-7 classiﬁcations. Association of 
BP control using mean SBP and antihypertensive class was deter-
mined. Medication persistence was calculated. Cox proportional
hazards analysis was performed to examine the hazard ratio
(HR) of discontinuation of medication class. RESULTS: A total
of 16,195 veterans obtained 49,254 antihypertensive medication
dispensings from August 12, 2002 to February 2, 2004. Of these,
4787 received monotherapy. For persons on monotherapy, mean
(SD) age was 64.9 +12.8 years; 93.4% were male. A total of 346
had normal SBP, but 4441 subjects had high SBP. Mean SBP
control was signiﬁcantly different between antihypertensive
classes(X2 = 7.9e + 3, p < 0.001). Use of beta-blockers and ACE-
inhibitors were more likely to be associated with subjects who
had controlled blood pressure, 47.1% and 23.1% respectively.
Among subjects with high SBP, beta-blockers and ACE-inhibitors
were used in 34.5% and 30.9% of subjects. The likelihood of
discontinuing therapy was statistically signiﬁcantly lower among
subjects receiving angiotensin receptor blockers (ARB), (HR
0.31, 95% CI 0.1–0.9). CONCLUSIONS: Among veterans
taking antihypertensive monotherapy, subjects on beta-blockers
were more likely to have controlled BP compared to other anti-
hypertensive medication classes. This could be due to high pre-
scribing rates, not necessarily success or failure as monotherapy.
Side effects/preference may lead to different persistence rates
between classes, but persons on ARBs were less likely to dis-
continue therapy. These results should be viewed cautiously since
the analysis may have been inﬂuenced by unmeasured patient
characteristics and formulary considerations.
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OBJECTIVES: In clinical trials the quality of life (QL) level was
a determinant of patient adherence to treatment, while such rela-
tionships during routine hypertension management are less clear.
The study aim was to evaluate predictors of self-reported adher-
ence to drug therapy and its relation to QL level in patients
referred to a specialized hypertension facility. METHODS: In 
a random sample of 238 hypertensives (116 males; aged 49
(43–57) years (median, quartile range)) we performed standard-
ized interview and QL assessment with validated questionnaires:
the General Well-Being Adjustment Scale and the Giessen
Somatic Complaints Questionnaire. Total Well-Being Index
(TWBI) and Total Complaints Intensity (TCI) were calculated in
groups of patients (GrA) treated on regular basis (62), (GrB)
those taking drugs irregularly (116), and (GrC) ones with known
but untreated hypertension (60). The same information was suc-
cessfully obtained by postal survey for 40 out of 104 patients
resided in city area after 61 months (range 32–73) of follow-up.
RESULTS: In GrC TWBI were the highest (88 (75–99.5) vs. 80
(69–88) in GrA, 80 (71–91.5) in GrB; p-value for Kruskal-Wallis
ANOVA 0.032), while TCI was the lowest (20.5 (10.5–34) vs.
33.5 (18–48) in GrA, 29 (16–38) in GrB; p = 0.003). Other com-
pliance predictors were age (42.5 (29.5–50) years in untreated
patients vs. 52 (46–59) in GrA, 50 (44–57) in GrB; p < 0.0001)
and gender (42% of men vs. 9% of women fell into GrC; p <
0.0001). During follow-up TWBI and TCI did not change sig-
niﬁcantly in any group, while TCI after follow-up was even
lower in patients twice reported absence of regular treatment (15
(12–29) in combined GrB+GrC vs. 36 (25–43) in GrA; p =
0.017). CONCLUSIONS: Long-term high QL level seems to be
related to low adherence to antihypertensive therapy. QL proﬁle
might be promising additional factor for risk stratiﬁcation during
routine hypertension management.
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OBJECTIVES: Hypertension and dyslipidemia elevate risk of
cardiovascular diseases in diabetic patients. The risk, however,
can be reduced considerably by drug therapy. Therefore, adher-
ence with prescribed drug therapy is especially important. The
study described adherence patterns of major drug classes of oral
antidiabetic (AD), antihypertensive (AH), and lipid-lowering
(LL) therapy in veterans with type 2 diabetes. METHODS: The
study used VA pharmacy prescription data from 1998 to 2004.
Patients were included if they initiated at least one of AD/AH/LL
in 2000. Concomitant therapy was deﬁned as initiating at least
two of AD/AH/LL within 90 days. Compliance was measured in
six-month intervals following initiation of therapy. Patients were
considered compliant if ﬁlled prescriptions were sufﬁcient for
covering >= 80% of days. Persistence was measured as the
number of days of continuous therapy, with 60 days between 2
prescriptions as the grace period. RESULTS: A total of 65,806,
31,910, and 48,445 patients were examined for adherence to
AD, AH, and LL, respectively. Angiotensin receptor blockers
(ARBs) had the longest mean persistence (AH, 787.7 days), fol-
lowed by â-blockers (AH, 764.7 days), sulfonylureas (AD, 734.7
days), ACE inhibitors (AH, 726.3 days), calcium channel block-
ers (AH, 708.1 days), metformin (AD, 700.0 days), á-blockers
(AH, 698.5 days), thiazolidinediones (AD, 674.0 days), statins
(LL, 663.6 days), diuretics (AH, 660.3 days), and ﬁbrates (LL,
557.8 days). Percentage of patients adherent with therapy
dropped sharply within ﬁrst 6 months, ranged from 49.4%
(ﬁbrates) to 66.8% (ARBs), and declined slowly afterwards.
ANOVA analyses indicated that concomitant therapy and use 
of Consolidated Mail Outpatient Pharmacy (CMOP) were 
associated with better compliance and longer persistence in 
most drug classes (P < 0.05), except ARBs (nonsigniﬁcant).
CONCLUSIONS: Adherence with AD, AH, and LL therapy in
veterans declines substantially over time. Adherence may be
improved by initiating AD, AH, and LL concomitantly and use
of CMOP.
